## Drug Repositioning Inferred from E2F1-Coregulator Int Prevention and Treatment of Metastatic Cancers

Theranostics 9, 1490-1509 DOI: 10.7150/thno.29546

**Citation Report** 

#	Article	IF	CITATIONS
1	Rewiring E2F1 with classical NHEJ via APLF suppression promotes bladder cancer invasiveness. Journal of Experimental and Clinical Cancer Research, 2019, 38, 292.	3.5	15
2	Evolving trends in pancreatic cancer therapeutic development. Annals of Pancreatic Cancer, 2019, 2, 17-17.	1.2	1
3	LncRNA-SLC16A1-AS1 induces metabolic reprogramming during Bladder Cancer progression as target and co-activator of E2F1. Theranostics, 2020, 10, 9620-9643.	4.6	58
4	Neural Networks Recapitulation by Cancer Cells Promotes Disease Progression: A Novel Role of p73 Isoforms in Cancer-Neuronal Crosstalk. Cancers, 2020, 12, 3789.	1.7	17
5	E2F transcription factor 1 (E2F1) promotes the transforming growth factor TGF-β1 induced human cardiac fibroblasts differentiation through promoting the transcription of CCNE2 gene. Bioengineered, 2021, 12, 6869-6877.	1.4	3
6	Drug Repositioning: Principles, Resources, and Application of Structure-Based Virtual Screening for the Identification of Anticancer Agents. , 2021, , 313-336.		2
7	Molecular Mechanisms and Animal Models of HBV-Related Hepatocellular Carcinoma: With Emphasis on Metastatic Tumor Antigen 1. International Journal of Molecular Sciences, 2021, 22, 9380.	1.8	1
8	Metastasis-associated protein 1: A potential driver and regulator of the hallmarks of cancer. Journal of Biosciences, 2022, 47, 1.	0.5	1
9	Melanoma 2.0. Skin cancer as a paradigm for emerging diagnostic technologies, computational modelling and artificial intelligence. Briefings in Bioinformatics, 2022, 23, .	3.2	3
10	3D Modeling of Non-coding RNA Interactions. Advances in Experimental Medicine and Biology, 2022, , 281-317.	0.8	2
11	Drug Repurposing at the Interface of Melanoma Immunotherapy and Autoimmune Disease. Pharmaceutics, 2023, 15, 83.	2.0	6